Search research articles
Contact Us
Filters
Showing results (11-20 of 47) with videos related to
Page
of 5
Sort By:
BMC Cancer
|
November 27, 2008
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
Véronique Ouellet, Tak Hay Ling, Karine Normandin, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 9, 2026
Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre-Operative PD1 CheckpOint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC)-A Phase 1B/2 Trial
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, et al.
Plos One
|
June 12, 2012
BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis
Cécile Le Page, Alexandre Marineau, Patrick K Bonza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2016
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore, Dario Strbenac, Ricardo Vilain, et al.
Histopathology
|
December 28, 2018
Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment
Tuba N Gide, Benjamin M Allanson, Alexander M Menzies, et al.
Leukemia
|
December 20, 2022
Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma
Mika Casey, Kane Segawa, Soi Cheng Law, et al.
BMC Cancer
|
May 30, 2008
Characterization of three new serous epithelial ovarian cancer cell lines
Véronique Ouellet, Magdalena Zietarska, Lise Portelance, et al.
Pigment Cell & Melanoma Research
|
December 6, 2014
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore, Ricardo E Vilain, Alexander M Menzies, et al.
International Journal of Cancer
|
December 7, 2017
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Stuart J Gallagher, Dilini Gunatilake, Kimberley A Beaumont, et al.
Breast Cancer Research : BCR
|
May 10, 2012
Crk adaptor proteins act as key signaling integrators for breast tumorigenesis
Kelly E Fathers, Emily S Bell, Charles V Rajadurai, et al.
Page
of 5
Search research articles
Search
Showing results (11-20 of 47) with videos related to
Sort By:
Page
of 5
BMC Cancer
|
November 27, 2008
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors
Véronique Ouellet, Tak Hay Ling, Karine Normandin, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 9, 2026
Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre-Operative PD1 CheckpOint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC)-A Phase 1B/2 Trial
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, et al.
Plos One
|
June 12, 2012
BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis
Cécile Le Page, Alexandre Marineau, Patrick K Bonza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 11, 2016
PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Jason Madore, Dario Strbenac, Ricardo Vilain, et al.
Histopathology
|
December 28, 2018
Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment
Tuba N Gide, Benjamin M Allanson, Alexander M Menzies, et al.
Leukemia
|
December 20, 2022
Inhibition of CD39 unleashes macrophage antibody-dependent cellular phagocytosis against B-cell lymphoma
Mika Casey, Kane Segawa, Soi Cheng Law, et al.
BMC Cancer
|
May 30, 2008
Characterization of three new serous epithelial ovarian cancer cell lines
Véronique Ouellet, Magdalena Zietarska, Lise Portelance, et al.
Pigment Cell & Melanoma Research
|
December 6, 2014
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
Jason Madore, Ricardo E Vilain, Alexander M Menzies, et al.
International Journal of Cancer
|
December 7, 2017
HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma
Stuart J Gallagher, Dilini Gunatilake, Kimberley A Beaumont, et al.
Breast Cancer Research : BCR
|
May 10, 2012
Crk adaptor proteins act as key signaling integrators for breast tumorigenesis
Kelly E Fathers, Emily S Bell, Charles V Rajadurai, et al.
Page
of 5